Keratitis in Dry Eye Disease and Topical Ciclosporin A

References

• Nichols KK. Patient-reported symptoms in dry dye disease. Ocul Surf. 2006;4(3):137–45.
   PubMed Web of Science ®Google Scholar
• Le Q, Zhou X, Ge L, et al. Impact of dry eye syndrome on vision-related quality of life in a non-clinic-based general population. BMC Ophthalmol. 2012;12:22.
   PubMed Web of Science ®Google Scholar
• Miljanovic B, Dana R, Sullivan DA, et al. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143(3):409–15.
   PubMed Web of Science ®Google Scholar
• The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75–92.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013;11(4):246–258.
   PubMed Web of Science ®Google Scholar
• Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol. 2008;146(3):350–356.
   PubMed Web of Science ®Google Scholar
• Benitez-del-Castillo JM, del Rio T, Iradier T, et al. Decrease in tear secretion and corneal sensitivity after laser in situ keratomileusis. Cornea 2001;20(1):30–32.
   PubMed Web of Science ®Google Scholar
• Miljanovic B, Trivedi KA, Dana MR, et al. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr. 2005;82(4):887–893.
   PubMed Web of Science ®Google Scholar
• Baudouin C. A new approach for better comprehension of diseases of the ocular surface. J Fr Ophtalmol. 2007;30(3):239–246.
   PubMed Web of Science ®Google Scholar
• Hessen M, Akpek EK. Dry eye: an inflammatory ocular disease. J Ophthalmic Vis Res. 2014;9(2):240–250.
   PubMedGoogle Scholar
• Kashani S, Mearza AA. Uses and safety profile of ciclosporin in ophthalmology. Expert Opin Drug Saf. 2008;7(1):79–89.
   PubMed Web of Science ®Google Scholar
• Borel JF, Feurer C, Magnee C, et al. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 1977;32(6):1017–1025.
   PubMed Web of Science ®Google Scholar
• Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54(3):321–338.
   PubMed Web of Science ®Google Scholar
• Korb DR. Survey of preferred tests for diagnosis of the tear film and dry eye. Cornea 2000;19(4):483–486.
   PubMed Web of Science ®Google Scholar
• Foulks GN. Challenges and pitfalls in clinical trials of treatments for dry eye. Ocul Surf. 2003;1(1):20–30.
   PubMedGoogle Scholar
• Lemp MA. Clinical trials in dry eye in surgery for dry eye? Dev Ophthalmol. 2008;41:283–297.
   PubMedGoogle Scholar
• Sullivan BD, Crews LA, Messmer EM, et al. Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. Acta Ophthalmologica 2014;92(2):161–166.
   PubMed Web of Science ®Google Scholar
• Schein OD, Tielsch JM, Munoz B, et al. Relation between signs and symptoms of dry eye in the elderly. A population-based perspective. Ophthalmology 1997;104(9):1395–1401.
   PubMed Web of Science ®Google Scholar
• Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22(7):640–650.
   PubMed Web of Science ®Google Scholar
• Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130(1):90–100.
   PubMedGoogle Scholar
• Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease. Int Rev Immunol. 2013;32(1):19–41.
   PubMed Web of Science ®Google Scholar
• Brignole F, Pisella PJ, Goldschild M, et al. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci. 2000;41(6):1356–1363.
   PubMed Web of Science ®Google Scholar
• Liu H, Begley C, Chen M, et al. A link between tear instability and hyperosmolarity in dry eye. Invest Ophthalmol Vis Sci. 2009;50(8):3671–3679.
   PubMed Web of Science ®Google Scholar
• Warcoin E, Baudouin C, Gard C, et al. In vitro inhibition of NFAT5-mediated induction of CCL2 in hyperosmotic conditions by cyclosporine and dexamethasone on human HeLa-Modified conjunctiva-derived cells. PLoS One 2016;11(8):e0159983.
   PubMed Web of Science ®Google Scholar
• Luo L, Li DQ, Pflugfelder SC. Hyperosmolarity-induced apoptosis in human corneal epithelial cells is mediated by cytochrome c and MAPK pathways. Cornea 2007;26(4):452–460.
   PubMed Web of Science ®Google Scholar
• Li DQ, Luo L, Chen Z, et al. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res. 2006;82(4):588–596.
   PubMed Web of Science ®Google Scholar
• El Annan J, Chauhan SK, Ecoiffier T, et al. Characterization of effector T cells in dry eye disease. Invest Ophthalmol Vis Sci. 2009;50(8):3802–3807.
   PubMed Web of Science ®Google Scholar
• Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006;25(8):900–907.
   PubMed Web of Science ®Google Scholar
• Murube J, Nemeth J, Hoh H, et al. The triple classification of dry eye for practical clinical use. Eur J Ophthalmol. 2005;15(6):660–667.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Aragona P, Van Setten G, et al. Diagnosing the severity of dry eye: a clear and practical algorithm. Br J Ophthalmol. 2014;98(9):1168–1176.
   PubMed Web of Science ®Google Scholar
• Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci. 2010;51(12):6125–6130.
   PubMed Web of Science ®Google Scholar
• Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea. 2004;23(8):762–770.
   PubMed Web of Science ®Google Scholar
• Miller KL, Walt JG, Mink DR, et al. Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol. 2010;128(1):94–101.
   PubMedGoogle Scholar
• Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):108–152.
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–558.
   PubMed Web of Science ®Google Scholar
• Johnson ME. The association between symptoms of discomfort and signs in dry eye. Ocul Surf. 2009;7(4):199–211.
   PubMed Web of Science ®Google Scholar
• Norn MS. Vital staining of cornea and conjunctiva. Acta Ophthalmol (Copenh). 1962;40:389–401.
   PubMed Web of Science ®Google Scholar
• Bron AJ, Argueso P, Irkec M, et al. Clinical staining of the ocular surface: mechanisms and interpretations. Prog Retin Eye Res. 2015;44:36–61.
   PubMed Web of Science ®Google Scholar
• Villani E, Magnani F, Viola F, et al. In vivo confocal evaluation of the ocular surface morpho-functional unit in dry eye. Optom Vis Sci. 2013;90(6):576–586.
   PubMed Web of Science ®Google Scholar
• Benitez-Del-Castillo JM, Acosta MC, Wassfi MA, et al. Relation between corneal innervation with confocal microscopy and corneal sensitivity with noncontact esthesiometry in patients with dry eye. Invest Ophthalmol Vis Sci. 2007;48(1):173–181.
   PubMed Web of Science ®Google Scholar
• Villani E, Galimberti D, Viola F, et al. The cornea in Sjogren’s syndrome: an in vivo confocal study. Invest Ophthalmol Vis Sci. 2007;48(5):2017–2022.
   PubMed Web of Science ®Google Scholar
• Cruzat A, Pavan-Langston D, Hamrah P. In vivo confocal microscopy of corneal nerves: analysis and clinical correlation. Semin Ophthalmol. 2010;25(5–6):171–177.
   PubMed Web of Science ®Google Scholar
• Tuisku IS, Konttinen YT, Konttinen LM, et al. Alterations in corneal sensitivity and nerve morphology in patients with primary Sjogren’s syndrome. Exp Eye Res. 2008;86(6):879–885.
   PubMed Web of Science ®Google Scholar
• Lin H, Li W, Dong N, et al. Changes in corneal epithelial layer inflammatory cells in aqueous tear-deficient dry eye. Invest Ophthalmol Vis Sci. 2010;51(1):122–128.
   PubMed Web of Science ®Google Scholar
• Bron AJ, Yokoi N, Gafney E, et al. Predicted phenotypes of dry eye: proposed consequences of its natural history. Ocul Surf. 2009;7(2):78–92.
   PubMed Web of Science ®Google Scholar
• Xu KP, Yagi Y, Tsubota K. Decrease in corneal sensitivity and change in tear function in dry eye. Cornea 1996;15(3):235–239.
   PubMed Web of Science ®Google Scholar
• Labbe A, Liang Q, Wang Z, et al. Corneal nerve structure and function in patients with non-sjogren dry eye: clinical correlations. Invest Ophthalmol Vis Sci. 2013;54(8):5144–5150.
   PubMed Web of Science ®Google Scholar
• Adatia FA, Michaeli-Cohen A, Naor J, et al. Correlation between corneal sensitivity, subjective dry eye symptoms and corneal staining in Sjogren’s syndrome. Can J Ophthalmol. 2004;39(7):767–771.
   PubMed Web of Science ®Google Scholar
• Toker E, Asfuroglu E. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy. Cornea 2010;29(2):133–140.
   PubMed Web of Science ®Google Scholar
• Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol. 2011;151(5):792–798e1.
   PubMed Web of Science ®Google Scholar
• Versura P, Profazio V, Campos EC. Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases. Curr Eye Res. 2010;35(7):553–564.
   PubMed Web of Science ®Google Scholar
• Lemp MA, Foulks GN, Pepose JS. Evaluation of tear osmolarity in non-Sjogren and Sjogren Syndrome dry eye patients with the TearLab system. Cornea. 2013;32(3):379–381.
   PubMed Web of Science ®Google Scholar
• Kaswan RL, Salisbury MA, Ward DA. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops. Arch Ophthalmol. 1989;107(8):1210–1216.
   PubMedGoogle Scholar
• Morgan RV, Abrams KL. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs. J Am Vet Med Assoc. 1991;199(8):1043–1046.
   PubMed Web of Science ®Google Scholar
• Power WJ, Mullaney P, Farrell M, et al. Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjogren’s syndrome. Cornea. 1993;12(6):507–511.
   PubMed Web of Science ®Google Scholar
• Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea. 1993;12(4):315–323.
   PubMed Web of Science ®Google Scholar
• Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology. 2000;107(5):967–974.
   PubMed Web of Science ®Google Scholar
• Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126(8):1046–1050.
   PubMedGoogle Scholar
• Zhou XQ, Wei RL. Topical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysis. Cornea. 2014;33(7):760–767.
   PubMed Web of Science ®Google Scholar
• Wan KH, Chen LJ, Young AL. Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis. Ocul Surf. 2015;13(3):213–225.
   PubMed Web of Science ®Google Scholar
• Chen M, Gong L, Sun X, Xie H, et al. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial. J Ocul Pharmacol Ther. 2010;26(4):361–366.
   PubMed Web of Science ®Google Scholar
• Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology 2007;114(1):76–79.
   PubMed Web of Science ®Google Scholar
• Su MY, Perry HD, Barsam A, et al. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy. Cornea 2011;30(10):1098–1104.
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Brown HC, et al. Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol 2009;127(2):146–152.
   PubMedGoogle Scholar
• Kara N, Altinkaynak H, Goker Y, et al. Evaluation of corneal morphologic and functional parameters after use of topical cyclosporine-a 0.05% in dry eye. J Ocul Pharmacol Ther 2012;28(6):593–597.
   PubMed Web of Science ®Google Scholar
• Tang-Liu DD, Acheampong A. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. Clin Pharmacokinet. 2005;44(3):247–261.
   PubMed Web of Science ®Google Scholar
• Robert PY, Leconte V, Olive C, et al. Cyclosporin A eyedrops: manufacturing, toxicity, pharmacokinetics and indications in 2000. J Fr Ophtalmol. 2001;24(5):527–535.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Daull P, Benita S, et al. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv. 2012;2012:604204.
   PubMedGoogle Scholar
• Tamilvanan S, Benita S. The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur J Pharm Biopharm. 2004;58(2):357–368.
   PubMed Web of Science ®Google Scholar
• Liang H, Baudouin C, Daull P, et al. Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model. Mol Vis. 2012;18:2195–2204.
   PubMed Web of Science ®Google Scholar
• Brignole F, Pisella PJ, De Saint Jean M, et al. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol. Vis Sci. 2001;42(1):90–95.
   Google Scholar
• Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287–296.
   PubMed Web of Science ®Google Scholar